Certara, Inc. (NASDAQ:CERT) Receives $15.67 Average PT from Brokerages

Certara, Inc. (NASDAQ:CERT - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight research firms that are presently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $15.67.

Several analysts recently issued reports on CERT shares. Barclays raised shares of Certara from an "equal weight" rating to an "overweight" rating and upped their price objective for the stock from $11.00 to $14.00 in a report on Thursday, May 8th. KeyCorp upped their price target on shares of Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a report on Wednesday, April 16th. Robert W. Baird lifted their price objective on Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. Stephens restated an "overweight" rating and set a $17.00 target price on shares of Certara in a research note on Thursday, February 27th. Finally, JMP Securities reaffirmed a "market perform" rating on shares of Certara in a report on Tuesday, May 6th.

Certara Stock Up 1.9%

NASDAQ CERT traded up $0.22 during trading on Friday, hitting $11.99. 1,235,543 shares of the company traded hands, compared to its average volume of 1,361,168. Certara has a 12 month low of $8.64 and a 12 month high of $16.93. The business has a fifty day simple moving average of $12.09 and a 200 day simple moving average of $11.87. The company has a market capitalization of $1.95 billion, a P/E ratio of -59.95, a PEG ratio of 9.29 and a beta of 1.44. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.04. The firm had revenue of $106.00 million during the quarter, compared to analyst estimates of $104.44 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The company's revenue for the quarter was up 9.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.10 EPS. As a group, sell-side analysts predict that Certara will post 0.28 EPS for the current year.

Hedge Funds Weigh In On Certara

Several large investors have recently added to or reduced their stakes in CERT. Versant Capital Management Inc increased its position in shares of Certara by 218.8% during the first quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock valued at $27,000 after purchasing an additional 1,866 shares during the period. Venturi Wealth Management LLC boosted its stake in Certara by 839.1% during the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock worth $30,000 after buying an additional 2,509 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Certara in the 1st quarter valued at $31,000. Wells Fargo & Company MN raised its stake in shares of Certara by 48.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock valued at $34,000 after buying an additional 1,047 shares in the last quarter. Finally, AlphaQuest LLC acquired a new position in shares of Certara in the 1st quarter valued at $39,000. Institutional investors and hedge funds own 73.96% of the company's stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.